Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bacillus coagulans TBC169
- Development stage
- Preclinical
- Lead developer
- Qingdao East Sea Pharmaceutical
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Bacillus coagulans TBC169 is a spore-forming probiotic strain developed and manufactured by Qingdao Eastsea Pharmaceutical Co., Ltd. in China. [7] It is formulated as live oral tablets and is considered a probiotic biologic or microecosystem drug. [7] The mechanism of action involves modulating the gut microbiota and intestinal function. [5] Specifically, it has been shown to inhibit the growth of harmful bacteria such as Enterobacteriaceae and influence metabolic pathways, including D-glutamine and D-glutamate metabolism, and arginine biosynthesis. [5, 6] Clinical studies have demonstrated that Bacillus coagulans TBC169 can accelerate the recovery of intestinal function following gynecological surgeries by reducing the time to first flatus and decreasing postoperative complications. [2, 3] It is also under investigation for the treatment of moderate-to-severe acne.
- Brand names
- Shuang Shu BaoBacillus coagulans Tablets, LiveBCTL
- Other names
- Bacillus coagulans strain TBC169
Beyond the preview
Go deeper on bacillus coagulans TBC169.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bacillus coagulans TBC169.